Momtaz, TanishaMonayem, Kazi Fahim2024-08-282024-08-28©20232023-11ID 18346083http://hdl.handle.net/10361/23930Cataloged from the PDF version of thesis.Includes bibliographical references (pages 33-35).This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.Hepatocellular carcinoma (HCC) is an important healthcare problem with developing therapeutic options. This meta-analysis evaluates the effectiveness and safety of lenvatinib and sorafenib, focusing largely on overall survival, progression-free survival, and adverse events. Both drugs promote overall and progression-free survival; however, lenvatinib outperforms the other in the latter regard. There are differences in safety profiles; sorafenib has larger confidence intervals and more prominent effects. Publication bias is negligible. Due to demographic considerations, care should be used when applying these results to different groups of people. This analysis contributes to our understanding of the therapeutic options for HCC by providing insightful information that researchers and healthcare providers may use when deciding on an option of treatment.49 pagesenBrac University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission.Hepatocellular carcinomaLenvatinibSorafenibDemographic analysisClinical decision makingRandomized controlled trialsProgression-free survivalLiver--Cancer--Treatment.Cancer--Molecular aspects.Thesis